Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials
Curative therapies or treatments reversing the progression of Parkinson’s disease (PD) have attracted considerable interest in the last few decades. PD is characterized by the gradual loss of dopaminergic (DA) neurons and decreased striatal dopamine levels. Current challenges include optimizing neur...
| Main Authors: | , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
2021
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/145662 |
| _version_ | 1811691981079838720 |
|---|---|
| author | Jang, Se Eun Qiu, Lifeng Chan, Ling Ling Tan, Eng-King Zeng, Li |
| author2 | Lee Kong Chian School of Medicine (LKCMedicine) |
| author_facet | Lee Kong Chian School of Medicine (LKCMedicine) Jang, Se Eun Qiu, Lifeng Chan, Ling Ling Tan, Eng-King Zeng, Li |
| author_sort | Jang, Se Eun |
| collection | NTU |
| description | Curative therapies or treatments reversing the progression of Parkinson’s disease (PD) have attracted considerable interest in the last few decades. PD is characterized by the gradual loss of dopaminergic (DA) neurons and decreased striatal dopamine levels. Current challenges include optimizing neuroprotective strategies, developing personalized drug therapy, and minimizing side effects from the long-term prescription of pharmacological drugs used to relieve short-term motor symptoms. Transplantation of DA cells into PD patients’ brains to replace degenerated DA has the potential to change the treatment paradigm. Herein, we provide updates on current progress in stem cell-derived DA neuron transplantation as a therapeutic alternative for PD. We briefly highlight cell sources for transplantation and focus on cell assessment methods such as identification of genetic markers, single-cell sequencing, and imaging modalities used to access cell survival and function. More importantly, we summarize clinical reports of patients who have undergone cell-derived transplantation in PD to better perceive lessons that can be drawn from past and present clinical outcomes. Modifying factors include (1) source of the stem cells, (2) quality of the stem cells, (3) age of the patient, (4) stage of disease progression at the time of cell therapy, (5) surgical technique/practices, and (6) the use of immunosuppression. We await the outcomes of joint efforts in clinical trials around the world such as NYSTEM and CiRA to further guide us in the selection of the most suitable parameters for cell-based neurotransplantation in PD. |
| first_indexed | 2024-10-01T06:28:31Z |
| format | Journal Article |
| id | ntu-10356/145662 |
| institution | Nanyang Technological University |
| language | English |
| last_indexed | 2024-10-01T06:28:31Z |
| publishDate | 2021 |
| record_format | dspace |
| spelling | ntu-10356/1456622023-03-05T16:48:37Z Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials Jang, Se Eun Qiu, Lifeng Chan, Ling Ling Tan, Eng-King Zeng, Li Lee Kong Chian School of Medicine (LKCMedicine) Science::Medicine Parkinson’s Disease Dopaminergic Neurons Curative therapies or treatments reversing the progression of Parkinson’s disease (PD) have attracted considerable interest in the last few decades. PD is characterized by the gradual loss of dopaminergic (DA) neurons and decreased striatal dopamine levels. Current challenges include optimizing neuroprotective strategies, developing personalized drug therapy, and minimizing side effects from the long-term prescription of pharmacological drugs used to relieve short-term motor symptoms. Transplantation of DA cells into PD patients’ brains to replace degenerated DA has the potential to change the treatment paradigm. Herein, we provide updates on current progress in stem cell-derived DA neuron transplantation as a therapeutic alternative for PD. We briefly highlight cell sources for transplantation and focus on cell assessment methods such as identification of genetic markers, single-cell sequencing, and imaging modalities used to access cell survival and function. More importantly, we summarize clinical reports of patients who have undergone cell-derived transplantation in PD to better perceive lessons that can be drawn from past and present clinical outcomes. Modifying factors include (1) source of the stem cells, (2) quality of the stem cells, (3) age of the patient, (4) stage of disease progression at the time of cell therapy, (5) surgical technique/practices, and (6) the use of immunosuppression. We await the outcomes of joint efforts in clinical trials around the world such as NYSTEM and CiRA to further guide us in the selection of the most suitable parameters for cell-based neurotransplantation in PD. Published version 2021-01-04T03:17:49Z 2021-01-04T03:17:49Z 2020 Journal Article Jang, S. E., Qiu, L., Chan, L. L., Tan, E.-K., & Zeng, L. (2020). Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials. Frontiers in Neuroscience, 14, 558532-. doi:10.3389/fnins.2020.558532 1662-4548 https://hdl.handle.net/10356/145662 10.3389/fnins.2020.558532 33177975 14 en Frontiers in Neuroscience © 2020 Jang, Qiu, Chan, Tan and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. application/pdf |
| spellingShingle | Science::Medicine Parkinson’s Disease Dopaminergic Neurons Jang, Se Eun Qiu, Lifeng Chan, Ling Ling Tan, Eng-King Zeng, Li Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials |
| title | Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials |
| title_full | Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials |
| title_fullStr | Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials |
| title_full_unstemmed | Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials |
| title_short | Current status of stem cell-derived therapies for Parkinson’s disease : from cell assessment and imaging modalities to clinical trials |
| title_sort | current status of stem cell derived therapies for parkinson s disease from cell assessment and imaging modalities to clinical trials |
| topic | Science::Medicine Parkinson’s Disease Dopaminergic Neurons |
| url | https://hdl.handle.net/10356/145662 |
| work_keys_str_mv | AT jangseeun currentstatusofstemcellderivedtherapiesforparkinsonsdiseasefromcellassessmentandimagingmodalitiestoclinicaltrials AT qiulifeng currentstatusofstemcellderivedtherapiesforparkinsonsdiseasefromcellassessmentandimagingmodalitiestoclinicaltrials AT chanlingling currentstatusofstemcellderivedtherapiesforparkinsonsdiseasefromcellassessmentandimagingmodalitiestoclinicaltrials AT tanengking currentstatusofstemcellderivedtherapiesforparkinsonsdiseasefromcellassessmentandimagingmodalitiestoclinicaltrials AT zengli currentstatusofstemcellderivedtherapiesforparkinsonsdiseasefromcellassessmentandimagingmodalitiestoclinicaltrials |